Liselotte Langkjaer

Title: Liselotte Langkjaer: Innovator in Insulin Formulations

Introduction

Liselotte Langkjaer is a prominent inventor based in Holte, Denmark. She has made significant contributions to the field of diabetes treatment through her innovative work on insulin formulations. With a total of 2 patents, her research focuses on improving the stability and efficacy of insulin solutions.

Latest Patents

Liselotte's latest patents include formulations of insulin that can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog. This advancement allows for the creation of stable insulin formulations that can enhance patient care. Additionally, she has developed novel insulin peptides characterized by amino acid residue changes at A21, which improve the stability of insulin solutions at acidic pH levels. Some of these insulin analogs also feature modifications in other amino acid residues, resulting in a charge difference compared to human insulin at a pH value of 7. These innovations may include substitutions for glutamic acid residues and optional blocking of the C-terminal carboxyl group of the B-chain.

Career Highlights

Liselotte Langkjaer is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. Her work at Novo Nordisk has positioned her as a key player in the development of advanced insulin therapies.

Collaborations

Throughout her career, Liselotte has collaborated with notable colleagues such as Jan Markussen and Kjeld Norris. These partnerships have contributed to her success in the field of insulin research and development.

Conclusion

Liselotte Langkjaer's innovative contributions to insulin formulations have the potential to significantly impact diabetes treatment. Her dedication to improving the stability and efficacy of insulin solutions showcases her commitment to advancing healthcare.